January 06, 2019 | News
06 January 2019, London, UK
Two co-founders of FabRx and leading UCL academics, Professor Abdul Basit and Professor Simon Gaisford, have brought together the world-leading experts to author their book on 3D printing in the pharmaceutical field. FabRx staff were invited to author several chapters, including Sarah Trenfield (Director of Innovation) and Alvaro Goyanes (Co-founder and Technical Director), with an aim to provide extensive information on an array of 3D printing techniques and their applications in clinical pharmacy practice.
Book summary: 3D printing is forecast to revolutionise the pharmaceutical sector, changing the face of medicine development, manufacture and use. Potential applications range from pre-clinical drug development and dosage form design through to the fabrication of functionalised implants and regenerative medicine. Within clinical pharmacy practice, printing technologies may finally lead to the concept of personalised medicines becoming a reality. This volume aims to be the definitive resource for anyone thinking of developing or using 3D printing technologies in the pharmaceutical sector, with a strong focus on the translation of printing technologies to a clinical setting. Current printing technologies and their state-of-the-art applications in the pharmaceutical manufacturing supply chain have been reviewed, as well as the discussion of modern drug product manufacture from a regulatory perspective. This book is a highly valuable resource for a range of demographics, including academic researchers and the pharmaceutical industry, providing a comprehensive inventory detailing the current and future applications of 3D printing in pharmaceuticals.
To find out more information or to purchase the book, please follow the link: https://www.springer.com/us/book/9783319907543. Free previews of each chapter are also available.
Copyright © 2022 FabRx Ltd